ImmunoGen Inc

ImmunoGen — JP Morgan Healthcare Conference 2022

31 slides from ImmunoGen's conference presentation, Jan 10, 2022

  1. Slide 1: Target a Better Now

    Slide 1: Target a Better Now

    CONFIDENTIAL1 TARGET A BETTER NOW JP Morgan Healthcare ConferenceJanuary 10-13, 2022NASDAQ: IMGN

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    CONFIDENTIAL2 FORWARD-LOOKING STATEMENTS Thispresentationincludesforward-lookingstatementsregardingImmunoGen’scurrentexpectationsrelatedto:thedesignandpotentialsuccessofImmunoGen’smirvetuximabsoravtansine,IMGN632,IMGC936,andIMGN151preclinicalandclinicalstudiesandregulatorypathways,includingthetiming

  3. Slide 3: Why ImmunoGen?

    Slide 3: Why ImmunoGen?

    CONFIDENTIAL3 WHY IMMUNOGEN? POISED TO BECOME A FULLY-INTEGRATED ONCOLOGY COMPANYWITH FIRST COMMERCIAL LAUNCH EXPECTED THISYEAR ACCELERATED PATH FOR MIRVETUXIMAB IN PROCPIVOTAL SORAYA STUDY MET PRIMARY ENDPOINTPREPARING BLA SUBMISSION MOVING MIRVETUXIMABINTO BROAD OVARIAN CANCER POPULATIONSPURSUING

  4. Slide 4: Significantly Advanced the Business in 2021

    Slide 4: Significantly Advanced the Business in 2021

    CONFIDENTIAL4 SIGNIFICANTLY ADVANCEDTHE BUSINESS IN 2021RECENT ACCOMPLISHMENTSMIRVETUXIMAB SORAVTANSINE•Reported positive topline pivotal data from SORAYA •Continued enrollment in MIRASOL•Initiated PICCOLO for patients with FRα-high recurrent platinum-sensitive ovarian cancer•Supported enrollment in

  5. Slide 5: Strategic Priorities

    Slide 5: Strategic Priorities

    CONFIDENTIAL5 FURTHER STRENGTHEN balance sheet and expand capabilities through drug discovery and development partnerships ADVANCEPORTFOLIO of earlier stage ADCs: IMGN632 in BPDCN and AMLIMGC936 in solid tumors IMGN151 in ovarian and other FRα-positive solid tumorsSTRATEGIC PRIORITIESBRINGING ANTIBO

  6. Slide 6: What's Next for Her?

    Slide 6: What's Next for Her?

    CONFIDENTIAL6 WHAT’S NEXT FOR HER?Someone you know has been diagnosed with ovarian cancer…6

  7. Slide 7: Ovarian Cancer Is the Leading Cause of Death from Gynecological Cancers

    Slide 7: Ovarian Cancer Is the Leading Cause of Death from Gynecological Cancers

    CONFIDENTIAL7 OVARIAN CANCER IS THE LEADING CAUSE OF DEATHFROM GYNECOLOGICAL CANCERS~14,000 DIE ANNUALLY FROM OVARIAN CANCER IN THE US1 DIAGNOSISSURGERYPLATINUM-SENSITIVEPLATINUM-RESISTANTPlatinum-based chemotherapy+/-PARPi/BEVmaintenance ~21,000 patientsdiagnosed annually1Disease progressionwithin

  8. Slide 8: Mirvetuximab Soravtansine Key Attributes

    Slide 8: Mirvetuximab Soravtansine Key Attributes

    CONFIDENTIAL8 MIRVETUXIMAB SORAVTANSINE KEY ATTRIBUTES•Novel ADC with distinct FRα-binding antibody, cleavable linker, and maytansinoidDM4 payload•Favorable tolerability profile1, 2•Demonstrated activity in patients with FRα-positive platinum-resistant and platinum-sensitive ovarian cancer1, 3•Sizea

  9. Slide 9: Single-Arm Pivotal Trial of Mirvetuximab in Platinum-Resistant Ovarian Cancer

    Slide 9: Single-Arm Pivotal Trial of Mirvetuximab in Platinum-Resistant Ovarian Cancer

    CONFIDENTIAL9 SINGLE-ARM PIVOTAL TRIAL OF MIRVETUXIMAB IN FRα-HIGH PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCERPOSITIVE TOP-LINE RESULTSPOTENTIAL FOR ACCELERATED APPROVAL •Platinum-resistant disease (PFI < 6 months)•FRα-high only•Prior bevacizumab required•Prior PARPiallowed•1 to 3 prior lines al

  10. Slide 10: Expanding the Mirvetuximab Label

    Slide 10: Expanding the Mirvetuximab Label

    CONFIDENTIAL10 EXPANDING THE MIRVETUXIMAB LABELMOVE INTO PLATINUM-SENSITIVE DISEASE AND BECOMETHE COMBINATION AGENT OF CHOICE IN OVARIAN CANCER 64% ORRFRα-HIGH RECURRENTOVARIAN CANCERn= 3380% ORR15 MOS mPFSFRα-MED and -HIGHn= 1064% ORRFRα-HIGH RECURRENTOVARIAN CANCERn= 11MIRVETUXIMAB + BEVACIZUMAB2,

  11. Slide 11: Market Segmentation in 2022

    Slide 11: Market Segmentation in 2022

    CONFIDENTIAL11 Numbers represent Company estimates of US patients with conditions covered by the Company’s targeted indications. Similar marketsize expected in Europe.Sources: Decision Resources Group, diagnosed drug-treatable patients 2021. Flatiron Ovarian Cancer Cohort. FRα: folate receptor alpha

  12. Slide 12: Mirvetuximab Launch Imperatives

    Slide 12: Mirvetuximab Launch Imperatives

    CONFIDENTIAL12 MIRVETUXIMAB LAUNCH IMPERATIVES Redefineexpectations for positive treatment outcomes with mirvetuximabin platinum-resistant ovarian cancerSeek broad payer access and reimbursement and deliver a seamless patient experienceEnsure a positive physician experience based on education and gu

  13. Slide 13: IMGN151: Follow-On Candidate for FRα-Targeting

    Slide 13: IMGN151: Follow-On Candidate for FRα-Targeting

    CONFIDENTIAL13 1AACR 2020 Poster; Ab, O., et al.FRα: folate receptor alpha; ADC: antibody-drug conjugate; IND: investigational new drug application; FPI: first patient in13KEY ATTRIBUTES•Next-generation anti-FRα ADC designed to address tumors with a broad range of FRα-expression (e.g., ovarian, endo

  14. Slide 14: What's Next for Them?

    Slide 14: What's Next for Them?

    CONFIDENTIAL14 14 WHAT’S NEXT FOR THEM?Someone you know has been diagnosed with a hematologic malignancy…

  15. Slide 15: IMGN632: Designed to Target CD123+ Hematologic Malignancies

    Slide 15: IMGN632: Designed to Target CD123+ Hematologic Malignancies

    CONFIDENTIAL15 IMGN632DESIGNED TO TARGET MULTIPLE CD123+ HEMATOLOGIC MALIGNANCIES1ASH 2018 Oral Presentation; Daver, N., et al. ASH 2019 Oral Presentation; Daver, N., et al.2ASH 2020 Oral Presentation; Pemmaraju, N., et al.CD123: Interleukin-3 receptor alpha chain; ADC: antibody drug conjugate; DNA:

  16. Slide 16: BPDCN Is a Rare and Aggressive Hematologic Malignancy

    Slide 16: BPDCN Is a Rare and Aggressive Hematologic Malignancy

    CONFIDENTIAL16 BPDCN IS A RARE AND AGGRESSIVEHEMATOLOGIC MALIGNANCY~500 TO ~1,000 NEW CASES DIAGNOSED ANNUALLY IN THE US160% TO 70% BECOME R/R INTENSIVE CHEMO OR TARGETED THERAPYDIAGNOSISSTEM CELL TRANSPLANTCHEMO OR TARGETED THERAPY Select casesOUTCOMESREMAIN POOR, PARTICULARLY FOR NON-TRANSPLANT CA

  17. Slide 17: IMGN632: Aligned with FDA on Path to Full Approval in BPDCN

    Slide 17: IMGN632: Aligned with FDA on Path to Full Approval in BPDCN

    CONFIDENTIAL17 IMGN632: ALIGNED WITH FDA ON PATH TO FULL APPROVAL IN BPDCN1ASH 2020 Oral Presentation; Pemmaraju, N., et al. 2ASH 2021 Abstract #1284; Pemmaraju, N., et al.FDA: US Food and Drug Administration; BPDCN: blastic plasmacytoid dendritic cell neoplasm; TEAE: treatment emergent adverse even

  18. Slide 18: AML Is an Aggressive Hematologic Malignancy

    Slide 18: AML Is an Aggressive Hematologic Malignancy

    CONFIDENTIAL18 AML IS AN AGGRESSIVEHEMATOLOGIC MALIGNANCY~20,000 PEOPLE DIAGNOSED WITH AMLAND ~11,000 DIE ANNUALLY IN THE US1 FIT PATIENTS2Approximately half of patients are“fit” enough to undergo intensive chemotherapy and transplant with curative intent Median survival: 2-4 yearsUNFIT PATIENTS2App

  19. Slide 19: IMGN632 in AML

    Slide 19: IMGN632 in AML

    CONFIDENTIAL19 1ASH 2021 Abstract #372; Daver, N., et al. AML: acute myeloid leukemia; COMBO: combination; ASH: American Society of Hematology; ORR: objective response rate; CCR: composite complete remission rate includes CR + CRh+ CRp+ CriVEN: Venclexta® (venetoclax); FLT3: FmsRelated Receptor Tyro

  20. Slide 20: IMGC936: First-in-Class ADAM9-Targeting ADC

    Slide 20: IMGC936: First-in-Class ADAM9-Targeting ADC

    CONFIDENTIAL20 IMGC936FIRST-IN-CLASSADAM9-TARGETING ADCKEY ATTRIBUTES•ADAM9 is overexpressed in multiple solid tumors (e.g., non-small cell lung, gastric, pancreatic, triple-negative breast, and colorectal)1with low levels of expression in normal tissue•IMGC936 comprised of a high-affinity humanized

  21. Slide 21: Our Approach to Partnering

    Slide 21: Our Approach to Partnering

    CONFIDENTIAL21 OUR APPROACH TO PARTNERINGMAXIMIZE THE VALUE OF OUR STRATEGIC PROGRAMS AND NOVEL ADCTECHNOLOGY BY RISK SHARING AND PARTNERING FOR CAPABILITIES IGN: indolinobenzodiazepinedimer Development and commercialization of mirvetuximab in Greater China Global co-development and co-commercializa

  22. Slide 22: Target a Better Now

    Slide 22: Target a Better Now

    CONFIDENTIAL22 TARGET A BETTER NOW POSITIVE TOP-LINE DATA GENERATED FOR LEAD MIRVETUXIMAB PROGRAMPLAN TO SUBMIT BLA IN Q1 2022 AND POTENTIAL ACCELERATED APPROVAL IN H2 2022INNOVATIVE EARLIER STAGE CANDIDATES IN SOLID TUMORSIMGC936: FIRST-IN-CLASS ADAM9-TARGETING ADC IN THE CLINIC IMGN151: NEXT-GENER

  23. Slide 23: Appendix

    Slide 23: Appendix

    CONFIDENTIAL23 Appendix

  24. Slide 24: Deep Pipeline of ADCs Targeting Solid Tumors and Hematologic Malignancies

    Slide 24: Deep Pipeline of ADCs Targeting Solid Tumors and Hematologic Malignancies

    CONFIDENTIAL24 DEEP PIPELINE OF ADCs TARGETINGSOLID TUMORS AND HEMATOLOGIC MALIGNANCIES ODD, FTODD ODD, BTDin BPDCNODD ADC: antibody-drug conjugate; FRα: folate receptor alpha; ODD: orphan drug designation; FT: fast track; BTD: breakthrough therapy designation; BPDCN: blastic plasmacytoid dendritic

  25. Slide 25: Phase 3 Randomized Trial for Mirvetuximab in Platinum-Resistant Ovarian Cancer

    Slide 25: Phase 3 Randomized Trial for Mirvetuximab in Platinum-Resistant Ovarian Cancer

    CONFIDENTIAL25 Mirvetuximab PHASE 3 RANDOMIZED TRIALFOR MIRVETUXIMAB IN FRα-HIGH PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER *Eligibility criterion different than SORAYAFRα: folate receptor alpha; IC: investigator’s choice; PLD: pegylated liposomal doxorubicin; PFS: progression-free survival; BI

  26. Slide 26: Single-Arm Trial for Mirvetuximab in Platinum-Sensitive Ovarian Cancer

    Slide 26: Single-Arm Trial for Mirvetuximab in Platinum-Sensitive Ovarian Cancer

    CONFIDENTIAL26 SINGLE-ARM TRIALFOR MIRVETUXIMABIN FRα-HIGH PATIENTS WITH PLATINUM-SENSITIVEOVARIAN CANCER PRIMARY ENDPOINT ORR by Investigator SECONDARY ENDPOINTDOR by InvestigatorNOW ENROLLING ENROLLMENT AND KEY ELIGIBILITY~75 patients Platinum-sensitive ovarian cancer 2 or more prior systemic trea

  27. Slide 27: Randomized Phase 3 Trial for Mirvetuximab + Bevacizumab Maintenance

    Slide 27: Randomized Phase 3 Trial for Mirvetuximab + Bevacizumab Maintenance

    CONFIDENTIAL27 RANDOMIZED PHASE 3 TRIALFOR MIRVETUXIMAB + BEVACIZUMAB MAINTENANCE IN FRα-HIGH PLATINUM-SENSITIVE OVARIAN CANCER PRIMARY ENDPOINT PFS SECONDARY ENDPOINTSOS, DOR ENROLLMENT AND KEY ELIGIBILITY438 patients Platinum-sensitive ovarian cancer 1 prior platinum treatmentPrior PARPi required

  28. Slide 28: Single-Arm Phase 2 Trial of Mirvetuximab + Carboplatin

    Slide 28: Single-Arm Phase 2 Trial of Mirvetuximab + Carboplatin

    CONFIDENTIAL28 SINGLE-ARM PHASE 2 TRIAL OF MIRVETUXIMAB + CARBOPLATIN FOLLOWED BY MIRVETUXIMAB CONTINUATION IN FRα-LOW, MEDIUM, AND HIGH PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER PRIMARY ENDPOINT ORR by Investigator SECONDARY ENDPOINTSDOR, PFS ENROLLMENT AND KEY ELIGIBILITY~110 patients Platin

  29. Slide 29: Study 801: Single-Arm Pivotal Cohort for IMGN632 in Frontline BPDCN

    Slide 29: Study 801: Single-Arm Pivotal Cohort for IMGN632 in Frontline BPDCN

    CONFIDENTIAL29 801 STUDY:SINGLE-ARM PIVOTAL COHORT FOR IMGN632 IN FRONTLINE BPDCN PRIMARY ENDPOINTCR plus CRc KEY SECONDARY ENDPOINTDuration of CR/CRc ENROLLMENT AND KEY ELIGIBILITYUp to 20 frontline patientsIncludes patients with prior local therapy Patients ≥18 years oldCD123+ by flow cytometry or

  30. Slide 30: ImmunoGen ADCs At-a-Glance

    Slide 30: ImmunoGen ADCs At-a-Glance

    CONFIDENTIAL30 IMMUNOGEN ADCs AT-A-GLANCE MIRVETUXIMAB SORAVTANSINEFolate receptor alpha-targeting ADC IMGN632CD123-targeting ADC IMGC936ADAM9-targeting ADC IMGN151Folate receptor alpha-targeting ADCANTIBODY: Humanizedmonoclonal antibody which selectively binds to FRαPAYLOAD: DM4 maytansinoid payloa

  31. Slide 31: CONFIDENTIAL31

    Slide 31: CONFIDENTIAL31

    CONFIDENTIAL31

Source: SEC EDGAR · 8-K filed Jan 10, 2022

More decks from ImmunoGen Inc